Who are BMS-986353's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Relma-cel, cART, IL-7/IL-15 pre-treated CD19 cells, SCTC21C, bb2121, CTX001.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bms-986353.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BMS-986353 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BMS-986353 (BMS-986353) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR-T cell therapy. Area: Oncology.

phase 3 CAR-T cell therapy Tumor-associated antigen (specific target not publicly disclosed in detail) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BMS-986353 (BMS-986353) — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. BMS-986353 is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BMS-986353 TARGET	BMS-986353	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	phase 3	CAR-T cell therapy	Tumor-associated antigen (specific target not publicly disclosed in detail)
Relma-cel	Relma-cel	Shanghai Ming Ju Biotechnology Co., Ltd.	marketed	CAR-T cell therapy
cART	cART	LI Taisheng	marketed	CAR-T cell therapy	Tumor-associated antigen (specific target depends on formulation)
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
SCTC21C	SCTC21C	Sinocelltech Ltd.	phase 3	CAR-T cell therapy
bb2121	bb2121	Celgene	phase 3	CAR-T cell therapy	BCMA (B-cell maturation antigen)
CTX001	CTX001	Vertex Pharmaceuticals Incorporated	phase 3	CAR-T cell therapy / Gene-edited T-cell therapy	BCMA (B-cell maturation antigen) / Tumor-associated antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR-T cell therapy class)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 3 drugs in this class
Chongqing Precision Biotech Co., Ltd · 2 drugs in this class
Guangzhou Women and Children's Medical Center · 2 drugs in this class
Sinocelltech Ltd. · 2 drugs in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Guangzhou Bio-gene Technology Co., Ltd · 1 drug in this class
Celyad Oncology SA · 1 drug in this class
Janssen Scientific Affairs, LLC · 1 drug in this class
EdiGene Inc. · 1 drug in this class
Hrain Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMS-986353 — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-986353. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab